Hereditäre Thrombophilien und Plazenta-medierte Schwangerschafts-komplikationen im II./III. Trimenon

W. Rath; C. J. Thaler

doi:10.5482/HAMO-12-11-0020

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 2013; 33(01): 21-36
DOI: 10.5482/HAMO-12-11-0020

Review

Schattauer GmbH

Hereditäre Thrombophilien und Plazenta-medierte Schwangerschafts-komplikationen im II./III. Trimenon

Hereditary thrombophilias and placentalmediated pregnancy complications in the II./III. trimester

Autor*innen

W. Rath

¹Gynäkologie und Geburtshilfe, Medizinische Fakultät, Universitätsklinikum Aachen
C. J. Thaler

²Hormon- und Kinderwunschzentrum, Klinikum LMU-Groß hadern, München

Abstract

Zusammenfassung

Plazenta-medierte Schwangerschaftskomplikationen (PmSk) wie Präeklampsie (PE), intra uterine Wachstumsrestriktion (IUGR) und vorzeitige Plazentalösung (VPL) sind häufige Ursachen mütterlicher und kindlicher Morbidität und Mortalität. Die hohe Prä -valenz in Casecontrol-Studien sowie morphologische Untersuchungen der Plazenta bei diesen Frauen legten die Vermutung einer Assoziation zwischen hereditären Thrombo-philien und PmSk nahe. Allerdings ist die Daten lage widersprüchlich, da nachfolgende prospektive Kohortenstudien und aktuelle Metaanalysen keinen signifikanten Zusam-menhang zwischen hereditären Thrombophilien und PmSk nachweisen konnten. Infolge der multifaktoriellen Ätiologie der PmSk dürfte es schwierig sein, zu beweisen, dass here-ditäre Thrombophilien unabhängige Risikofaktoren für PmSk sind.

Aktuelle Leitlinien empfehlen keine Untersuchung auf hereditäre Thrombophilien nach vorangegangenen PmSk. Aktuelle In-vitro-Studien zeigten positive nicht antikoagulatorische Wirkungen von niedermolekularen Heparinen (NMH) auf die frühe Plazentation. Retrospektive Case-control-Studien sowie neue randomisierte und prospektive Studien ergaben, dass durch die Gabe von NMH ab der Frühschwangerschaft eine signifikante Sen-kung des Wiederholungsrisikos für PmSk in nachfolgenden Schwangerschaften bei Frauen mit und ohne hereditäre Thrombophilien zu erreichen ist. Schlussfolgerung: Große randomisierte Multizenterstudien sind notwendig, um die Bedeutung hereditärer Thrombophilien für PmSk und den Nutzen einer Prävention mit NMH zu klären.

Summary

Placental-mediated pregnancy complications (PmC) like preeclampsia, intrauterine growth restriction and placental abruption are common causes of fetal and maternal morbidity and mortality. The high prevalence of hereditary thrombophilias in case-control studies associated with pathological morphological findings of the placenta in these cases gave evidence for the association between hereditary thrombophilias and PmC. However, data from the literature are inconsistent, since subsequent prospective cohort studies could not demonstrate significant associations between inherited thrombophilia and PmC. Because of the multifactorial aetiology of PmC it may be difficult to prove, that hereditary thrombophilias are independent risk factors for PmC.

Current guidelines do not recommend screening for inherited thrombophilias in patients with previous PmC. Evidence from current in vitro studies have shown, that heparin has beneficial non-anticoagulatory effects on trophoblast invasion. Retrospective case-control studies and recently published randomised controlled cohort studies have shown, that prophylactic administration of low-molecular-weight heparin (LWH), started in early pregnancy, may lead to a significant reduction in the incidence of PmC in subsequent pregnancies in patients with and without hereditary thrombophilias and previous PmC. Conclusion: Large, well-designed multicenter studies are needed to elucidate the role of hereditary thrombophilias in cases of PmC and to confirm the benefit of LWH for subsequent pregnancy outcomes.

Schlüsselwörter

Hereditäre Thrombophilien - Plazenta-medierte Schwangerschaftskomplikationen - Emp-fehlungen zur Diagnostik - Prävention mit nieder molekularen Heparinen

Keywords

Hereditary thrombophilia - placental- mediated pregnancy complications - recommendations for screening - prevention with low-molecular-weight heparin

Volltext

Referenzen

Literatur
1 Woodham PC, Bogess KA, Gardner Mo, Doyle NM. Routine antenatal thrombophilia screening in high-risk pregnancies: a decision analysis. Am J Perinatol 2011; 28: 495-500.
2 Kupferminc M, Eldor A, Steinman N. et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999; 340: 9-13.
3 Preston FE, Rosendaal FR, Walter JD. et al. Increased fetal loss in women with hereditable thrombophilia. Lancet 1996; 348: 913-916.
4 Dekker GA, de Vries JIP, Doelitzsch PM. et al. Underlying disorders associated with severe earlyonset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048.
5 Isermann B, Sood R, Pawlinski R. et al. Thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 09: 258-260.
6 Kist W, Janssen NG, Kalk JJ. et al. Thrombophilias and adverse pregnancy outcome - a confounded problem. Thromb Haemost 2008; 99: 77-85.
7 Benedetto C, Marozio L, Tarella AM. et al. Coagulation disorders in pregnancy: acquired and inherited thrombophilias. Ann NY Acad Sci 2010; 1205: 106-117.
8 Rodger MA, Paidas M, Claire M. et al. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 2008; 112: 320-324.
9 Rodger MA, Betancourt MT, Clark P. et al. The association of factor V and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and metaanalysis of prospective cohort studies. PLoS Med 2010; 07: e1000292.
10 D’Ippolito S, Ortiz AS, Vaglia M. et al. Low molecular weight heparin in obstetric care: a review of the literature. Reprod Sci 2011; 18: 602-613.
11 Robertson L, Wu O. for the Thrombosis, Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
12 Tempelhoff von G-F, Koscielny J, Rath W. Thrombophilie und Schwangerschaftskomplikationen. Geburtsh Frauenheilk 2011; 71: 105-118.
13 Morrison ER, Miedzybrodzka ZH, Campbell DM. et al. Prothrombotic genotypes are not associated with preeclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-785.
14 Kosmas IP, Tatsioni A, Joannidis JPA. Association of Leiden mutation in factor V gene with hypertension in pregnancy and preeclampsia: a metaanalysis. J Hypotension 2003; 21: 1221-1228.
15 Lin J, August Ph. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005; 105: 182-192.
16 Dizon-Townson D, Miller C, Sibai BM. et al. The relationship of the factor V leiden mutation and pregnancy outcome for mother and fetus. Obstet Gynecol 2005; 106: 517-524.
17 Mello G, Paretti E, Marozia L. et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale case-controlled study. Hypertension 2005; 46: 1270-1274.
18 Mütze S, Leeners B, Ortlepp JR. et al. Maternal factor V leiden mutation is associated with HELLP syndrome in Caucasian women. Acta Obstet Gynecol 2008; 87: 635-642.
19 Mütze S, Eggermann T, Leeners B. et al. The 4G/5G polymorphismus in the plasminogen activator inhibitor-1 gene is not associated with HELLP syndrome. J Thromb Thrombolysis 2009; 27: 141-145.
20 Wiwanitkit V. Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal. Arch Gynecol Obstet 2006; 273: 322-324.
21 Rath W. Preeclampsia and inherited thrombophilia. Semin Thromb Hemost 2011; 37: 118-124.
22 Facchinetti F, Marozio L, Frusca T. et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200: 46e1-46e5.
23 Van Rijn BB, Hocks LB, Bots ML. et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195: 723-728.
24 Mütze S, Rudnik-Schönborn S, Rath W. Genes and the preeclampsia syndrome. J Perinat Med 2008; 36: 38-58.
25 Kahn SR, Platt R, Mc Namara H. et al. Inherited thrombophilia and preeclampsia within a multicenter cohort the Montreal Preeclampsia Study. Am J Obstet Gynecol 2009; 200: 151e1-e9.
26 Xia XP, Chong WW, Cao YX. Meta-analysis of the methylenetetrahydrofolate reductase C 677T polymosphism and susceptibility to pre-eclampsia. Hypertens Res 2012; 35: 1129-1134.
27 De Bonis M, Sabatini L, Gallazzi L. et al. Maternal serum protein S forms in pregnancies complicated by intrauterine growth restriction. Eur J Obstet Gynecol Reprod Biol 2012; 160: 142-146.
28 Schleußner E. Mütterliche Gerinnungsstörungen: Pathologie im zweiten und dritten Trimenon. Gynäkologe 2011; 44: 515-520.
29 Many A, Schreiber L, Rosner S. et al. Pathologic features of the placenta in women with severe pregnancy complication and thrombophilia. Obstet Gynecol 2001; 98: 1041-1044.
30 Beeksma FA, Erwich JJHM, Khong YY. Placental fetal vascular thrombotic lesions and maternal thrombophilia. Pathology 2012; 44: 24-28.
31 Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004; 191: 412-424.
32 Kupferminc MJ, Many A, Bar-Am A. et al. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG 2002; 109: 1373-1376.
33 Kupferminc MJ, Peri H, Zwang E. et al. High prevalence of the prothrombin gene mutation in women with intrauterine growth restriction, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 2000; 79: 963-967.
34 Howley HEA, Walker M, Rodger MA. A systematic review of the association between factor V leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005; 192: 694-708.
35 Infante-Rivard C, Rivard GE, Yotov WV. et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347: 19-25.
36 Dudding T, Heron J, Thakkinstian A. et al. Factor V leiden is associated with preeclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost 2008; 06: 1868-1875.
37 Facco F, You W, Grobman W. Genetic thrombophilias and intrauterine growth restriction - a metaanalysis. Obstet Gynecol 2009; 113: 1206-1216.
38 Silver RM, Zhao Y, Spong CJ. et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010; 115: 14-20.
39 Said JM, Higgins JR, Moses EK. et al. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 2010; 115: 5-13.
40 Kjellberg U, van Rooijen M, Brenner K, Hellgren M. Factor V leiden mutation and pregnancy-related complications. Am J Obstet Gynecol 2010; 203: 469e1-469e8.
41 Bennett SA, Bagot CN, Arya R. Pregnancy loss and thrombophilia: the elusive link. Br J Haematol 2012; 157: 529-542.
42 Rey E, Kahn SR, David M, Shrier I. Thrombophilia disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.
43 Larciprete G, Rossi F, Deaibess T, Brienza L. et al. Double inherited thrombophilias and adverse pregnancy outcomes: Fashion or science?. J Obstet Gynaecol Res 2010; 36: 996-1002.
44 Kocher O, Cirovic C, Malynn E. et al. Obstetric complications in patients with hereditary thrombophilia using the LCx microparticle enzyme immunoassay: a controlled study of 5000 patients. Am J Clin Path 2007; 127: 68-75.
45 Hiltunen LM, Laivuori H, Routanen A. et al. Factor V leiden as risk factor for unexplained stillbirth - a population based nested case-control study. Thromb Res 2010; 125: 505-510.
46 Helgadottir LB, Skjeldestad FE, Jacobsen AF. et al. The association of inherited thrombophilia and intrauterine fetal death: a case-control study. Blood Coagul Fibrinolysis 2011; 22: 651-656.
47 Brenner B. Thrombophilia and pregnancy loss. Thromb Res 2002; 108: 197-202.
48 Simchen MJ, Ofir K, Moran O. et al. Thrombophilia risk factors for placenta stillbirth. Eur J Obstet Gynecol Reprod Biol 2010; 153: 160-164.
49 Monari F, Alberico S, Avagliano L. et al. Relation between maternal thrombophilia and stillbirth according to causes/associated correlations of death. Early Human Development 2012; 88: 254.
50 Korteweg FJ, Folkeringa N, Brouwer J-CP. et al. Fetal loss in women with hereditary thrombophilic defects and concomitance of other thrombophilic defects: a retrospective family study. BJOG 2012; 119: 422-430.
51 Weichert J, Hartge DR, Lüdders DW. et al. Fetale Thrombophilie. Gynäkologe 2011; 44: 521-526.
52 Facchinetti F, Marozio L, Grandone E. et al. Thrombophilia mutations are a main risk factor for placental abruption. Haemotologica 2003; 88: 785-788.
53 Prochazka M, Lubusky M, Slavik L. et al. Frequency of selected thrombophilias in women with placental abruption. Aust NZJ Obstet Gynaecol 2007; 47: 297-301.
54 Nath CA, Ananth CV, De Marco C. et al. Low birthweight in relation to placental abruption and maternal thrombophilia status. Am J Obstet Gynecol 2008; 198: 293e1-293e5.
55 Nurk E, Tell GS, Refsum H. et al. Associations between maternal methylenetetrahydrofolae reductase polymorphism and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J Med 2004; 117: 26-31.
56 Duhl AJ, Paidas MJ, Ural SH. et al. for the Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197: 457e1-457e5.
57 Bates SM, Greer IA, Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines. Chest. 2012. 141 (Suppl): e691S-e736S.
58 ACOG Practice Bulletin No. 113. Inherited thrombophilias in pregnancy. Obstet Gynecol 2011; 118: 730-739.
59 Abou-Nassar K, Kovacs MJ, Kahn SR. et al. The effect of dalteparin on coagulation activataion during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98: 163-171.
60 Tersigni C, Marana R, Santamaria A. et al. In vitro evidences of heparin’s effects on embryo implantation and trophoblast development. Reprod Sci 2012; 19: 454-462.
61 Kingdom JCP, Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies?. Blood 2011; 118: 4780-4788.
62 Rodger MA. Anticoagulant prophylaxis for placenta mediated pregnancy complications. Thromb Res 2011; 127 (Suppl): 576-580.
63 Kupferminc MJ, Fait G, Many A. et al. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy 2001; 20: 35-44.
64 Grandone E, Brancaccio V, Colaizzo D. et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78: 371-375.
65 Kalk JJ, Huisjes AJM, de Groot CJM. et al. Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecularweight heparin treatment?. Neth J Med 2004; 62: 83-87.
66 Leduc L, Dubois E, Takser L. et al. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can 2007; 29: 787-793.
67 Kupferminc MJ, Rimon E, Many A. et al. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern-Fetal Neonatal Med 2011; 24: 1042-1045.
68 De Vries JIP, van Pompus MG, Hague WM. et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset preeclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2011; 10: 64-72.
69 Mello G, Parretti E, Fatini C. et al. Low-molecularweight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45: 86-91.
70 Rey E, Garneau P, David M. et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 07: 58-64.
71 Gris JC, Chauleur C, Faille JL. et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae: the pilot randomised controlled NOH-AP trial. Thromb Haemost 2010; 104: 771-779.
72 Gris JC, Chauleur C, Molinari N. et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: the pilot randomised controlled NOH-PE trial. Thromb Haemost 2011; 106: 1053-1061.
73 Kupferminc M, Rimon E, Many A. et al. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis 2011; 22: 123-126.
74 Conserva V, Muggiasca M, Arrigoni L. et al. Recurrence and severity of abnormal pregnancy outcomes in patients treated by low-molecular-weight heparin: a prospective pilot study. J Matern-Fetal Neonatal Med 2012; 25: 1467-1473.
75 Norrie G, Farquharson RG, Greaves M. Screening and treatment for heritable thrombophilia in pregnancy failure: inconsistencies among UK early pregnancy units. Br J Haematol 2008; 144: 241-244.